Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies - Oleaga, Carlota; Shapiro, Michael D.; Hay, Joshua; Mueller, Paul A.; Miles, Joshua; Huang, Cecilia; Friz, Emily; Tavori, Hagai; Toth, Peter P.; Wójcik, Cezary; Warden, Bruce A.; Purnell, Jonathan Q.; et al. (Journal of the American College of Cardiology, 2021)
Keywords: Adult; Aged; Animals; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Cardiovascular; cholesterol homeostasis; Female; Healthy Volunteers; HEK293 Cells; Humans; Hypercholesterolemia - drug therapy; LDL cholesterol; LDL receptor; Lipid Metabolism - drug effects; Liver - drug effects; Liver - metabolism; Male; Mice; Mice, Knockout; Middle Aged; monoclonal antibodies; PCSK9; PCSK9 Inhibitors - pharmacology; PCSK9 Inhibitors - therapeutic use; Proprotein Convertase 9 - blood; Receptors, LDL - blood; Retrospective Studies; turnover studies; turnover studies; PCSK9i; cholesterol homeostasis; SREBP; LDL-C; PCSK9; LDL cholesterol; LDLR; WT; LDL receptor; monoclonal antibodies; proprotein convertase subtilisin/kexin type 9; low-density lipoprotein receptor; low-density lipoprotein cholesterol; low-density lipoprotein receptor deficient mice; wild type; sterol regulatory element-binding protein; proprotein convertase subtilisin/kexin type 9 inhibitory therapy with monoclonal antibodies